Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5581936 | 0.77 | ALDH1A1 (0.44) | ALDH1A1APOBEC3AAPOBEC3GLMNAACHE | |
| Iodide SCHEMBL5581954 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL9478010 | 0.74 | ALDH1A1 (0.50) | ALDH1A1LMNAACHE | |
| Iodide SCHEMBL5581355 | 0.74 | ACHE (0.44) | ALDH1A1ACHE | |
| Bromide SCHEMBL5581074 | 0.73 | ALDH1A1 (0.44) | ALDH1A1LMNAACHESMN1; SMN2 | |
| Fluoride Ion SCHEMBL18740626 | 0.73 | HDAC8 (0.48) | ALDH1A1APOBEC3AAPOBEC3GHDAC8BCHE | |
| SCHEMBL10266186 | 0.73 | ALDH1A1 (0.52) | ALDH1A1APOBEC3AAPOBEC3GHDAC8CYP2C19 | |
| Iodide SCHEMBL5581465 | 0.72 | ALDH1A1 (0.42) | ALDH1A1CYP2C19LMNAACHE | |
| Iodide SCHEMBL5581997 | 0.71 | ALDH1A1 (0.46) | ALDH1A1APOBEC3AAPOBEC3GLMNA | |
| Iodide SCHEMBL5581390 | 0.70 | ACHE (0.48) | ALDH1A1CYP2C19ACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655653-B1 | METHODS AND COMPOUNDS FOR DETECTING CANCER | UNIV CARDIFF (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-20140370520-A1 | METHODS AND COMPOUNDS FOR DETECTING CANCER | University College Cardiff Constultants Limited (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2655653-A2 | METHODS AND COMPOUNDS FOR DETECTING CANCER | University College Cardiff Consultants Limited (GB) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085532-A2 | METHODS AND COMPOUNDS FOR DETECTING CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| US-20070166296-A1 | Therapeutic Systems | ENZACTA R & D LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-7138122-B2 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-0988059-B8 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | PROTHERICS MOLECULAR DESIGN LT (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-0988059-B1 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6867231-B1 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2005-03-15 | — | — | US | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
| EP-0988059-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057662-A2 | THERAPEUTIC SYSTEMS | ENZACTA R & D LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | NQO2, NQO1, NAPRT | ACHE 4315/4885ALDH1A1 1498/4885APOBEC3A 2996/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | ACHE 4315/4885ALDH1A1 1498/4885APOBEC3A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.